SMNDC1

Across TCGA pan-cancer cohorts, SMNDC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMNDC1 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMNDC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMNDC1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where SMNDC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.860	0.664	.002	12	view →
LSCC	OS	Tertile	II,III,IV	0.944	0.632	.018	6	view →
GBM	OS	Quartile	All	0.573	0.324	.037	3	view →
CCRCC	OS	Tertile	All	0.897	1.000	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMNDC1–PDAC (DFS)

Open the PDAC breakdown →